A Phase I Study of 225Ac-Lintuzumab in Patients With Multiple Myeloma Progressing After . 3 Prior Anti-MM Regimens or Refractory to QUAD (Carfilzomib, Lenalidomide, Pomalidomide, and Dexamethasone)

Trial Profile

A Phase I Study of 225Ac-Lintuzumab in Patients With Multiple Myeloma Progressing After . 3 Prior Anti-MM Regimens or Refractory to QUAD (Carfilzomib, Lenalidomide, Pomalidomide, and Dexamethasone)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Lintuzumab Ac-225 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Actinium Pharmaceuticals
  • Most Recent Events

    • 13 Sep 2017 According to an Actinium Pharmaceuticals media release, updates from the study will be presented at the Society of Hematologic Oncology 2017 Annual Meeting (SOHO).
    • 15 Jun 2017 According to an Actinium Pharmaceuticals media release, the company expects to readout topline data from this study in 2018.
    • 22 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top